Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 3

Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT ID: NCT07321652Sponsor: Alliance for Clinical Trials in OncologyLast updated: 2026-06-16

Summary

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Zanubrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantel cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Giving sonrotoclax and zanubrutinib may be more effective than zanubrutinib alone for the treatment of untreated CLL/SLL.

Detailed description

PRIMARY OBJECTIVES: I. To compare the progression free survival (PFS) between minimal residual disease (MRD)-guided zanubrutinib sonrotoclax therapy to continuous zanubrutinib as control. II. To determine the PFS comparing fixed duration zanubrutinib sonrotoclax therapy to continuous zanubrutinib as control. SECONDARY OBJECTIVES: I. To compare the PFS between the patients with MRD-detectable disease treated with fixed duration zanubrutinib sonrotoclax to the PFS of the patients with MRD detectable disease who receive one additional year of combination therapy. II. To determine the overall survival of all arms of the study. III. To determine the frequency of patients with MRD-detectable disease who convert to undetectable MRD, and at what depth and for how long, after receiving an extra year of combination therapy on the MRD-guided zanubrutinib sonrotoclax therapy arm. IV. To determine and compare the overall response rate (ORR defined as PR, CR, CCR, CRi) and complete remission rate (CR) after 14 cycles of therapy among the three arms. V. To compare time to the next CLL/SLL therapy among treatment arms. VI. To determine the rates and severity of toxicity in each arm, with a particular focus on adverse events of special interest that include infections, cardiovascular events (arrhythmias, heart failure, hypertension), tumor lysis syndrome, bleeding events, cytopenias, and second malignancies. VII. To compare patient-reported symptomatic adverse events as assessed by the Patient Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE) between arms 1 and 2. EXPLORATORY OBJECTIVES: I. To compare the best achieved rate of undetectable MRD (uMRD) between the fixed duration zanubrutinib sonrotoclax arm and the MRD guided zanubrutinib sonrotoclax arm. II. To compare rates of undetectable MRD measured by the immunoglobulin heavy chain (IGH) sequencing assay ClonoSeq (sensitivity 1 in 10\^-6) to undetectable MRD measured by standard six-color flow cytometry (uMRD4), and to compare results from bone marrow to peripheral blood. OUTLINE: Patients are randomized to 1 of 2 arms. ARM 1: Patients receive zanubrutinib orally (PO) twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo restaging starting at cycle 15 day 1. Patients with at least partial remission continue therapy as described above. Patients with progressive disease proceed to follow up. Patients undergo computed tomography (CT) scan, bone marrow aspiration and blood sample collection throughout the study. ARM 2: Patients receive zanubrutinib PO BID on days 1-28 of each cycle. Starting cycle 4 day 1 patients also receive sonrotoclax PO daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo restaging starting at cycle 15 day 1. Patients with undetectable MRD and a response of PR, partial response with persistent lymphocytosis (PR-L), CR, CCR or CRi stop therapy at cycle 15 day 28 and proceed to follow up. Patients with detectable MRD and an objective response to therapy are re-randomized to arm 2B or arm 2C. ARM 2B: Patients continue zanubrutinib PO BID sonrotoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for an additonal 12 cycles in the absence of disease progression or unacceptable toxicity. ARM 2C: Patients discontinue therapy starting at cycle 15 day 28 and proceed to follow up. Patients undergo CT scan, bone marrow aspiration and blood sample collection throughout the study. After completion of study treatment, patients are followed up every 3 months for 3 years then every 6 months until 10 years for study registration. Patients with progression or the start of non protocol CLL directed therapy are followed every 6 months for 10 years from registration.

Arms & interventions

  • DrugZanubrutinib

    Given PO

  • DrugSonrotoclax

    Given PO

  • ProcedureComputed Tomography

    Undergo CT scan

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow aspiration

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

  • OtherSurvey Administration

    Ancillary studies

Outcome measures

Primary

  • Progression free survival (PFS)

    From initial randomization date until the earlier of disease progression or death from any cause. PFS estimates for zanubrutinib plus sonrotoclax therapy to continuous Zanubrutinib.

    Time frame: From initial randomization date until the earlier of disease progression or death from any cause, up to 10 years

Eligibility criteria

Sex: AllAge: 65 Years and olderHealthy volunteers: No
Inclusion Criteria: * STEP 0: This bone marrow or peripheral blood submission to Adaptive is mandatory prior to registration/randomization for real-time identification of the clone needed for MRD testing. The bone marrow sample should be from the first aspiration (i.e., first pull). Aspirate needle should be redirected if needed to get first pull bone marrow aspirate. It should be obtained as soon after pre-registration as possible to confirm registration eligibility * STEP 0: Patients must be diagnosed with CLL/SLL according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2018 criteria that includes all of the following: * ≥ 5 x10\^9 /L B lymphocytes (5000/μL) in the peripheral blood (CLL) or a lymph node biopsy demonstrating SLL with the below immunophenotype (SLL) * On morphologic review, the leukemic cells must be small mature lymphocytes * Immunophenotype of CLL cells (performed locally) must reveal a clonal B-cell population, which coexpress the B cell surface markers of CD19 and CD20, as well as the T-cell antigen CD5. Patients with bright surface immunoglobulin expression or lack of CD23 expression in \> 10% of cells must lack t(11;14) translocation by interphase cytogenetics * STEP 0: Patients must meet criteria for treatment as defined by IWCLL 2018 guidelines which includes at least one of the following criteria: * Evidence of marrow failure as manifested by the development or worsening of anemia or thrombocytopenia (not attributable to autoimmune hemolytic anemia or thrombocytopenia), typically hemoglobin (Hb) \< 10 g/dL, platelet count \< 100,000/mm\^3 * Massive (\> 6 cm below the costal margin), progressive or symptomatic splenomegaly * Massive nodes (ie, \> 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy * Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard therapy * Constitutional symptoms, which include any of the following: * Unintentional weight loss of ≥ 10% within the previous 6 months * Significant fatigue (ie. Eastern Cooperative Oncology Group \[ECOG\] performance status \[PS\] ≥ 2) * Fevers \>100.5 °F or 38.0°C for 2 weeks or more without evidence of infection * Night sweats \> 1 month without evidence of infection * STEP 0: Patients must not have had prior therapy for CLL (except palliative steroids or treatment of autoimmune complications of CLL with rituximab or steroids) * STEP 0: Treatment with rituximab and/or high-dose corticosteroids for autoimmune complications of CLL must be completed prior to enrollment. Palliative steroids must be at a dose not higher than 20 mg/day of prednisone or equivalent corticosteroid at the time of registration * STEP 0: Age ≥ 65 years * STEP 0: ECOG performance status ≤ 2 * STEP 0: Patients with known HIV infection on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial * STEP 0: For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * STEP 0: Patients with a history of hepatitis C virus (HCV), infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * STEP 0: Patients must not be receiving active systemic anticoagulation with warfarin. Patients must be off warfarin therapy for at least 5 half-lives washout and with normal INR prior to enrollment * STEP 0: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients must be class 2B or better. Patients with acute cardiac events within 6 months prior to registration should be carefully evaluated for their suitability for enrollment * STEP 0: No patients with a history of a severe bleeding disorder or a history of hemorrhagic stroke or intracranial hemorrhage * STEP 0: No patients with known active progressive central nervous system (CNS) disease * STEP 0: No known medical condition causing an inability to swallow oral formulations of agents * STEP 1: The adaptive report confirming a measurable and trackable B cell clone * STEP 1: Patients may not have had major surgery within 7 days of enrollment, or minor surgery within 5 days of enrollment. Examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint. The decision about whether a surgery is major or minor can be made at the discretion of the treating physician * STEP 1: No patients with ongoing active fungal, bacterial or viral infection requiring systemic therapy except those described in the protocol document * STEP 1: Patients must not require more than 20 mg prednisone or equivalent corticosteroid daily * STEP 1: Patients must not have uncontrolled active systemic infection requiring intravenous antibiotics * STEP 1: Patients must not have continued requirement for therapy with a strong CYP3A4/5 inhibitor or inducer. Any such inhibitor or inducer must have been discontinued at least 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug * STEP 1: Absolute neutrophil count (ANC) ≥ 1,000/mm3 unless due to marrow involvement * STEP 1: Platelet count ≥ 30,000/mm3 * STEP 1: Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless due to liver involvement, hemolysis or Gilbert's disease) * STEP 1: Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/ alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3.0 x upper limit of normal (ULN) unless due to disease infiltration of the liver * STEP 1: Calculated (calc.) creatinine clearance by Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) ≥ 30 mL/min * STEP 1: Urine protein to creatinine ratio \< 1 or urine protein ≤ 1+ * STEP 2: Detectable MRD ≥ 10 residual clonal cells per million nucleated cells in peripheral blood at the C15 restaging evaluation from ClonoSEQ * STEP 2: Response of PR, PR-L, CR, CCR or CRi to zanubrutinib sonrotoclax therapy

Study locations (141)

Cedars-Sinai Medical Center

Los Angeles, California, 90048

Recruiting
Site Public Contact · Contact
310-423-2133Cancer.trial.info@cshs.org
Justin M. Darrah · Principal Investigator

Jupiter Medical Center

Jupiter, Florida, 33458

Recruiting
Site Public Contact · Contact
561-263-5791clinicaltrials@jupitermed.com
Ryan H. Devine · Principal Investigator

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Saint Alphonsus Cancer Care Center-Caldwell

Caldwell, Idaho, 83605

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Idaho Urologic Institute-Meridian

Meridian, Idaho, 83642

Recruiting
Site Public Contact · Contact
734-712-3671stephanie.couch@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
Christopher M. Reynolds · Principal Investigator

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Illinois CancerCare-Bloomington

Bloomington, Illinois, 61704

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Canton

Canton, Illinois, 61520

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Carthage

Carthage, Illinois, 62321

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Northwestern University

Chicago, Illinois, 60611

Recruiting
Site Public Contact · Contact
312-695-1301cancer@northwestern.edu
Shuo Ma · Principal Investigator

Carle at The Riverfront

Danville, Illinois, 61832

Recruiting
Site Public Contact · Contact
800-446-5532Research@Carle.com
Suparna Mantha · Principal Investigator

Cancer Care Specialists of Illinois - Decatur

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Decatur Memorial Hospital

Decatur, Illinois, 62526

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Dixon

Dixon, Illinois, 61021

Recruiting
Site Public Contact · Contact
815-285-7800
Bryan A. Faller · Principal Investigator

Carle Physician Group-Effingham

Effingham, Illinois, 62401

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Suparna Mantha · Principal Investigator

Illinois CancerCare-Eureka

Eureka, Illinois, 61530

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Galesburg

Galesburg, Illinois, 61401

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Kewanee Clinic

Kewanee, Illinois, 61443

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Macomb

Macomb, Illinois, 61455

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Suparna Mantha · Principal Investigator

Carle BroMenn Medical Center

Normal, Illinois, 61761

Recruiting
Site Public Contact · Contact
800-446-5532Research@Carle.com
Suparna Mantha · Principal Investigator

Carle Cancer Institute Normal

Normal, Illinois, 61761

Recruiting
Site Public Contact · Contact
800-446-5532Research@Carle.com
Suparna Mantha · Principal Investigator

Cancer Care Center of O'Fallon

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

HSHS Saint Elizabeth's Hospital

O'Fallon, Illinois, 62269

Recruiting
Site Public Contact · Contact
217-876-4762morganthaler.jodi@mhsil.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Ottawa Clinic

Ottawa, Illinois, 61350

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Pekin

Pekin, Illinois, 61554

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Peoria

Peoria, Illinois, 61615

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Peru

Peru, Illinois, 61354

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Illinois CancerCare-Princeton

Princeton, Illinois, 61356

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

Memorial Hospital East

Shiloh, Illinois, 62269

Recruiting
Site Public Contact · Contact
314-747-9912dschwab@wustl.edu
Dilan A. Patel · Principal Investigator

Southern Illinois University School of Medicine

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
217-545-7929
Bryan A. Faller · Principal Investigator

Springfield Clinic

Springfield, Illinois, 62702

Recruiting
Site Public Contact · Contact
800-444-7541
Bryan A. Faller · Principal Investigator

Springfield Memorial Hospital

Springfield, Illinois, 62781

Recruiting
Site Public Contact · Contact
217-528-7541pallante.beth@mhsil.com
Bryan A. Faller · Principal Investigator

Carle Cancer Center

Urbana, Illinois, 61801

Recruiting
Site Public Contact · Contact
800-446-5532Research@carle.com
Suparna Mantha · Principal Investigator

Illinois CancerCare - Washington

Washington, Illinois, 61571

Recruiting
Site Public Contact · Contact
309-243-3605andersonj@illinoiscancercare.com
Bryan A. Faller · Principal Investigator

UI Health Care Mission Cancer and Blood - Ankeny Clinic

Ankeny, Iowa, 50023

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Saint Anthony Regional Hospital

Carroll, Iowa, 51401

Recruiting
Site Public Contact · Contact
515-689-7658sbenson@iora.org
Seema Harichand-Herdt · Principal Investigator

Mercy Hospital

Cedar Rapids, Iowa, 52403

Recruiting
Site Public Contact · Contact
319-365-4673
Deborah W. Wilbur · Principal Investigator

Oncology Associates at Mercy Medical Center

Cedar Rapids, Iowa, 52403

Recruiting
Site Public Contact · Contact
319-363-2690
Deborah W. Wilbur · Principal Investigator

UI Health Care Mission Cancer and Blood - West Des Moines Clinic

Clive, Iowa, 50325

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Iowa Methodist Medical Center

Des Moines, Iowa, 50309

Recruiting
Site Public Contact · Contact
515-241-6727
Seema Harichand-Herdt · Principal Investigator

UI Health Care Mission Cancer and Blood - Des Moines Clinic

Des Moines, Iowa, 50309

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Broadlawns Medical Center

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-282-2200
Seema Harichand-Herdt · Principal Investigator

Mercy Medical Center - Des Moines

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-241-3305
Richard L. Deming · Principal Investigator

UI Health Care Mission Cancer and Blood - Laurel Clinic

Des Moines, Iowa, 50314

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

UI Healthcare Mission Cancer and Blood - Fort Dodge

Fort Dodge, Iowa, 50501

Recruiting
Site Public Contact · Contact
515-282-2921trials@missioncancer.com
Seema Harichand-Herdt · Principal Investigator

UI Healthcare Mission Cancer and Blood - Pella

Pella, Iowa, 50219

Recruiting
Site Public Contact · Contact
515-282-2921trials@missioncancer.com
Seema Harichand-Herdt · Principal Investigator

UI Health Care Mission Cancer and Blood - Waukee Clinic

Waukee, Iowa, 50263

Recruiting
Site Public Contact · Contact
515-241-3305
Seema Harichand-Herdt · Principal Investigator

Cancer Center of Kansas - Chanute

Chanute, Kansas, 66720

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

Cancer Center of Kansas - Dodge City

Dodge City, Kansas, 67801

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

Cancer Center of Kansas - El Dorado

El Dorado, Kansas, 67042

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

Cancer Center of Kansas-Independence

Independence, Kansas, 67301

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

University of Kansas Cancer Center

Kansas City, Kansas, 66160

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Marc S. Hoffmann · Principal Investigator

Cancer Center of Kansas-Kingman

Kingman, Kansas, 67068

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

Cancer Center of Kansas-Liberal

Liberal, Kansas, 67905

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

Cancer Center of Kansas - McPherson

McPherson, Kansas, 67460

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

Cancer Center of Kansas - Newton

Newton, Kansas, 67114

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

The University of Kansas Cancer Center - Olathe

Olathe, Kansas, 66061

Recruiting
Site Public Contact · Contact
913-588-1569OlatheCCResearch@kumc.edu
Marc S. Hoffmann · Principal Investigator

University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, 66210

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Marc S. Hoffmann · Principal Investigator

Cancer Center of Kansas - Parsons

Parsons, Kansas, 67357

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

Cancer Center of Kansas - Pratt

Pratt, Kansas, 67124

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

Cancer Center of Kansas - Salina

Salina, Kansas, 67401

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

Cancer Center of Kansas - Wellington

Wellington, Kansas, 67152

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Marc S. Hoffmann · Principal Investigator

Cancer Center of Kansas-Wichita Medical Arts Tower

Wichita, Kansas, 67208

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

Ascension Via Christi Hospitals Wichita

Wichita, Kansas, 67214

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

Cancer Center of Kansas - Wichita

Wichita, Kansas, 67214

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

Cancer Center of Kansas - Winfield

Winfield, Kansas, 67156

Recruiting
Site Public Contact · Contact
316-291-4774research@viachristi.org
Dennis F. Moore · Principal Investigator

The James Graham Brown Cancer Center at University of Louisville

Louisville, Kentucky, 40202

Recruiting
Site Public Contact · Contact
502-562-3429
Hassaan Yasin · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912

Recruiting
Site Public Contact · Contact
517-364-3712harsha.trivedi@umhsparrow.org
Christopher M. Reynolds · Principal Investigator

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197

Recruiting
Site Public Contact · Contact
734-712-7251MCRCwebsitecontactform@stjoeshealth.org
Christopher M. Reynolds · Principal Investigator

Sanford Joe Lueken Cancer Center

Bemidji, Minnesota, 56601

Recruiting
Site Public Contact · Contact
218-333-5000OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Essentia Health Saint Joseph's Medical Center

Brainerd, Minnesota, 56401

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health - Deer River Clinic

Deer River, Minnesota, 56636

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Cancer Center

Duluth, Minnesota, 55805

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Hibbing Clinic

Hibbing, Minnesota, 55746

Recruiting
Site Public Contact · Contact
218-786-3308
Bret E. Friday · Principal Investigator

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Yan Ji · Principal Investigator

Regions Hospital

Saint Paul, Minnesota, 55101

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Yan Ji · Principal Investigator

United Hospital

Saint Paul, Minnesota, 55102

Recruiting
Site Public Contact · Contact
952-993-1517mmcorc@healthpartners.com
Yan Ji · Principal Investigator

Essentia Health Sandstone

Sandstone, Minnesota, 55072

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Essentia Health Virginia Clinic

Virginia, Minnesota, 55792

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Saint Francis Medical Center

Cape Girardeau, Missouri, 63703

Recruiting
Site Public Contact · Contact
573-334-2230sfmc@sfmc.net
Bryan A. Faller · Principal Investigator

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Dilan A. Patel · Principal Investigator

Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Dilan A. Patel · Principal Investigator

Parkland Health Center - Farmington

Farmington, Missouri, 63640

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

University of Kansas Cancer Center - Briarcliff

Kansas City, Missouri, 64116

Recruiting
Site Public Contact · Contact
913-588-3671
Marc S. Hoffmann · Principal Investigator

University of Kansas Cancer Center - North

Kansas City, Missouri, 64154

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Marc S. Hoffmann · Principal Investigator

University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064

Recruiting
Site Public Contact · Contact
913-588-3671KUCC_Navigation@kumc.edu
Marc S. Hoffmann · Principal Investigator

Sainte Genevieve County Memorial Hospital

Sainte Genevieve, Missouri, 63670

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

Washington University School of Medicine

St Louis, Missouri, 63110

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Dilan A. Patel · Principal Investigator

Siteman Cancer Center-South County

St Louis, Missouri, 63129

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Dilan A. Patel · Principal Investigator

Missouri Baptist Medical Center

St Louis, Missouri, 63131

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136

Recruiting
Site Public Contact · Contact
800-600-3606info@siteman.wustl.edu
Dilan A. Patel · Principal Investigator

Missouri Baptist Sullivan Hospital

Sullivan, Missouri, 63080

Recruiting
Site Public Contact · Contact
314-996-5569
Bryan A. Faller · Principal Investigator

Community Hospital of Anaconda

Anaconda, Montana, 59711

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Billings Clinic Cancer Center

Billings, Montana, 59101

Recruiting
Site Public Contact · Contact
800-996-2663research@billingsclinic.org
John M. Schallenkamp · Principal Investigator

Benefis Sletten Cancer Institute

Great Falls, Montana, 59405

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Logan Health Medical Center

Kalispell, Montana, 59901

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Community Medical Center

Missoula, Montana, 59804

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
John M. Schallenkamp · Principal Investigator

Jefferson Cherry Hill Hospital

Cherry Hill, New Jersey, 08002

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Michael Wysota · Principal Investigator

Sidney Kimmel Cancer Center Washington Township

Sewell, New Jersey, 08080

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Michael Wysota · Principal Investigator

University of Rochester

Rochester, New York, 14642

Recruiting
Site Public Contact · Contact
585-275-5830
Paul M. Barr · Principal Investigator

Wilmot Cancer Institute at Webster

Webster, New York, 14580

Recruiting
Site Public Contact · Contact
WCICTOresearch@urmc.rochester.edu
Paul M. Barr · Principal Investigator

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599

Recruiting
Site Public Contact · Contact
877-668-0683cancerclinicaltrials@med.unc.edu
Christopher E. Jensen · Principal Investigator

Duke University Medical Center

Durham, North Carolina, 27710

Recruiting
Site Public Contact · Contact
888-275-3853
Danielle M. Brander · Principal Investigator

Margaret R Pardee Memorial Hospital

Hendersonville, North Carolina, 28791

Recruiting
Site Public Contact · Contact
828-696-4716pardeecancerresearch@unchealth.unc.edu
John K. Hill · Principal Investigator

Sanford Bismarck Medical Center

Bismarck, North Dakota, 58501

Recruiting
Site Public Contact · Contact
701-323-5760OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Essentia Health Cancer Center-South University Clinic

Fargo, North Dakota, 58103

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Sanford Broadway Medical Center

Fargo, North Dakota, 58122

Recruiting
Site Public Contact · Contact
701-323-5760OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122

Recruiting
Site Public Contact · Contact
701-234-6161OncologyClinicalTrialsFargo@sanfordhealth.org
Daniel Almquist · Principal Investigator

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

Recruiting
Site Public Contact · Contact
800-293-5066Jamesline@osumc.edu
Jennifer A. Woyach · Principal Investigator

Saint Alphonsus Cancer Care Center-Baker City

Baker City, Oregon, 97814

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
Christopher M. Reynolds · Principal Investigator

Providence Newberg Medical Center

Newberg, Oregon, 97132

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Saint Alphonsus Cancer Care Center-Ontario

Ontario, Oregon, 97914

Recruiting
Site Public Contact · Contact
406-969-6060mccinfo@mtcancer.org
Christopher M. Reynolds · Principal Investigator

Providence Willamette Falls Medical Center

Oregon City, Oregon, 97045

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Providence Portland Medical Center

Portland, Oregon, 97213

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Providence Saint Vincent Medical Center

Portland, Oregon, 97225

Recruiting
Site Public Contact · Contact
503-215-2614CanRsrchStudies@providence.org
Alison K. Conlin · Principal Investigator

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Michael Wysota · Principal Investigator

Jefferson Torresdale Hospital

Philadelphia, Pennsylvania, 19114

Recruiting
Site Public Contact · Contact
215-600-9151ONCTrialNow@jefferson.edu
Michael Wysota · Principal Investigator

Sanford Cancer Center Oncology Clinic

Sioux Falls, South Dakota, 57104

Recruiting
Site Public Contact · Contact
605-312-3320OncologyClinicTrialsSF@sanfordhealth.org
Daniel Almquist · Principal Investigator

Sanford USD Medical Center - Sioux Falls

Sioux Falls, South Dakota, 57117-5134

Recruiting
Site Public Contact · Contact
605-312-3320OncologyClinicalTrialsSF@SanfordHealth.org
Daniel Almquist · Principal Investigator

Swedish Cancer Institute-Edmonds

Edmonds, Washington, 98026

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Alison K. Conlin · Principal Investigator

Swedish Cancer Institute-Issaquah

Issaquah, Washington, 98029

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Alison K. Conlin · Principal Investigator

Swedish Medical Center-First Hill

Seattle, Washington, 98122

Recruiting
Site Public Contact · Contact
206-215-2343PCRC-NCORP@Swedish.org
Alison K. Conlin · Principal Investigator

Duluth Clinic Ashland

Ashland, Wisconsin, 54806

Recruiting
Site Public Contact · Contact
218-786-3308CancerTrials@EssentiaHealth.org
Bret E. Friday · Principal Investigator

Saint Vincent Hospital Cancer Center Green Bay

Green Bay, Wisconsin, 54301

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Anthony J. Jaslowski · Principal Investigator

Saint Vincent Hospital Cancer Center at Saint Mary's

Green Bay, Wisconsin, 54303

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Anthony J. Jaslowski · Principal Investigator

Gundersen Lutheran Medical Center

La Crosse, Wisconsin, 54601

Recruiting
Site Public Contact · Contact
608-775-2385cancerctr@gundersenhealth.org
Michael O. Ojelabi · Principal Investigator

ProHealth D N Greenwald Center

Mukwonago, Wisconsin, 53149

Recruiting
Site Public Contact · Contact
research.institute@phci.org
Timothy R. Wassenaar · Principal Investigator

ProHealth Oconomowoc Memorial Hospital

Oconomowoc, Wisconsin, 53066

Recruiting
Site Public Contact · Contact
262-928-7878
Timothy R. Wassenaar · Principal Investigator

Saint Vincent Hospital Cancer Center at Oconto Falls

Oconto Falls, Wisconsin, 54154

Recruiting
Site Public Contact · Contact
920-433-8889WI_research_admin@hshs.org
Anthony J. Jaslowski · Principal Investigator

Saint Vincent Hospital Cancer Center at Sturgeon Bay

Sturgeon Bay, Wisconsin, 54235-1495

Recruiting
Site Public Contact · Contact
920-433-8889wi_research_admin@hshs.org
Anthony J. Jaslowski · Principal Investigator

UW Cancer Center at ProHealth Care

Waukesha, Wisconsin, 53188

Recruiting
Site Public Contact · Contact
262-928-5539Chanda.miller@phci.org
Timothy R. Wassenaar · Principal Investigator
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL | Cancerify